The growth of the global IgA nephropathy treatment market is being driven by the rising prevalence of the disease, which is currently rising at a growth rate of 0.02%. The prevalence is likely to grow further in the forecast period with the rising diagnosis of the disease.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
IgA nephropathy, also known as Berger's disease, is a chronic kidney disorder that happens when the deposits of an antibody, known as immunoglobulin A (IgA), starts building up in the kidneys. Immunoglobulin A (IgA) is an antibody, a protein, which is produced by the immune system to fight any foreign substances like bacteria and virus that can cause infections. When these IgA deposits start building up in the kidney, leads to inflammation that can even damage the functioning of the kidney. In this condition, the kidneys are unable to filter the waste, and this can lead to severe renal disorders after a while. The disease takes long to progress, an average of 10 to 20 years, however it can vary from person to person.
While the exact cause of the disorder continues to be ambiguous, some of the possible causes of the diseases can include genes, liver ailments like cirrhosis, hepatitis B and hepatitis C infections, celiac disease, and several other infections like HIV and bacterial infections.
The condition, if not taken care of, can lead to complications like high blood pressure, high cholesterol, acute kidney failure, nephrotic syndrome, cardiovascular disorders, and other chronic kidney disorders.
The disease does not cause obvious signs and symptoms in the beginning, which is why it is mostly not diagnosed in the initial stages even for decades. It is mostly diagnosed when the protein and red blood cells in the urine are detected to be higher than normal. The most common diagnostic methods to detect the condition include checking the medical history of the patient and their family, physical test, urine test, and blood test, among others. The signs and symptoms of the condition can include the presence of blood in urine or brownish urine, foamy urine due to the higher presence of protein, pain in the lower part of the ribs in the back, swollen hands and feet, high blood pressure, among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market can be categorised into segments like diagnostic methods, treatment method, disease type, symptoms, age group, route of administration, treatment channel, distribution channel of drugs, end-user, and major regional markets.
Market Breakup by Diagnosis Method
Market Breakup by Treatment Method
Market Breakup by Disease Type
Market Breakup by Symptoms
Market Breakup by Age Group
Market Breakup by Route of Administration
IgA Nephropathy Treatment Market Breakup by Treatment Channel
Market Breakup by Distribution Channel of Drugs
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market for IgA nephropathy treatment has been witnessing robust growth during the historical period due to the rise in the prevalence of chronic kidney disorders, technological advancements in the treatment sector, and the increasing demand for timely diagnosis of the disease. The Asia Pacific region is anticipated to witness significant demand over the forecast period as the prevalence of kidney disorder is rising at an alarming rate. The rising awareness about the condition, growth in the number of diagnostic techniques, as well as the rising approval od advanced and effective drugs is also propelling the growth of the market.
Within the Asia Pacific region, Japan and China are anticipated to be the leading contributors to the rising demand owing to the rising kidney cancer cases and the rapidly growing pharmaceutical sector in these countries.
This condition is most likely to occur to people suffering from diabetes or high blood pressure. The condition can happen at any age but is more common between teenagers and middle-aged people. Men are more likely to suffer from this disease, the chances are almost double. Based on region, it is more common amongst people belonging to Asian and European origins.
There is no absolute cure for the disease yet, but the treatments and therapies available in the market can help prevent the further progression of the disease and also help relieve the current symptoms. These treatments can be as follows:
Regulating food habits plays a pivotal role in controlling the symptoms of this condition and the patient must be extremely cautious of the food choices they make in order to prevent any further damage.
The report gives an in-depth analysis of the key players involved in the IgA nephropathy treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Diagnosis Method||
|Breakup by Treatment Method||
|Breakup by Disease Type||
|Breakup by Symptoms||
|Breakup by Age Group||
|Breakup by Route of Administration||
|Breakup by Treatment Channel||
|Breakup by Distribution Channel||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 IgA Nephropathy Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
126.96.36.199 Patent Status and Expiry
188.8.131.52 Timelines from Drug Development to Commercial Launch
184.108.40.206 New Drug Application
220.127.116.11.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
18.104.22.168 US FDA
22.214.171.124 EU EMA
126.96.36.199 INDIA CDSCO
188.8.131.52 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Rate
7.3 Awareness and Prevention Gaps
8 Global IgA Nephropathy Treatment Market
8.1 Global IgA Nephropathy Treatment Market Overview
8.2 Global IgA Nephropathy Treatment Market Analysis
8.2.1 Market Overview
184.108.40.206 Global IgA Nephropathy Treatment Market Historical Value (2016-2022)
220.127.116.11 Global IgA Nephropathy Treatment Market Forecast Value (2023-2031)
8.3 Global IgA Nephropathy Treatment Market by Diagnosis Method
8.3.1 Market Overview
18.104.22.168 Blood Test
22.214.171.124 Urine Test
126.96.36.199 Kidney Biopsy
188.8.131.52 Iothalamate Clearance Test
8.4 Global IgA Nephropathy Treatment Market by Treatment Method
8.4.1 Market Overview
184.108.40.206 Corticosteroid Drugs
220.127.116.11 Immunosuppressive Drugs
18.104.22.168 ACE inhibitors and ARBs
8.5 Global IgA Nephropathy Treatment Market by Disease Type
8.5.1 Market Overview
22.214.171.124 Primary IgA Nephropathy
126.96.36.199 Secondary IgA Nephropathy
8.6 Global IgA Nephropathy Treatment Market by Symptoms
8.6.1 Market Overview
8.7 Global IgA Nephropathy Treatment Market by Age Group
8.7.1 Market Overview
8.8 Global IgA Nephropathy Treatment Market by Route of Administration
8.8.1 Market Overview
8.9 Global IgA Nephropathy Treatment Market by Treatment Channel
8.10 Global IgA Nephropathy Treatment Market by Distribution Channel
8.10.1 Market Overview
188.8.131.52 Hospital Pharmacy
184.108.40.206 Retail Pharmacy
220.127.116.11 Online Pharmacy
18.104.22.168 Direct Tender
8.11 Global IgA Nephropathy Treatment Market by End User
8.11.1 Market Overview
22.214.171.124 Home Healthcare
8.12 Global IgA Nephropathy Treatment Market by Region
8.12.1 Market Overview
126.96.36.199 North America
188.8.131.52 Asia Pacific
184.108.40.206 Latin America
220.127.116.11 Middle East and Africa
9 North America IgA Nephropathy Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe IgA Nephropathy Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
11 Asia Pacific IgA Nephropathy Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
12 Latin America IgA Nephropathy Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
13 Middle East and Africa IgA Nephropathy Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
14 Global IgA Nephropathy Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Novartis AG
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Calliditas Therapeutics AB
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Chinook Therapeutics Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Travere Therapeutics Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Omeros Corporation
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 VIFOR Pharma
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Vera Therapeutics Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Merck KGaA
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Reata Pharmaceuticals Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Ionis Pharmaceuticals Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.11 Apellis Pharmaceuticals Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.12 Otsuka Pharmaceutical Co. Ltd
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
16 Global IgA Nephropathy Treatment Market - Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The prevalence of the disease is likely to rise at a growth rate of more than 0.02% during the forecast period owing to the rising awareness.
The growth of the market is driven by factors like rising awareness about the disease, growing technological advancements, poor eating habits, and rising lifestyle disorders.
The rising drug and treatment approvals act as key trends for the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The diagnosis methods used for the condition include blood test, urine test, kidney biopsy, ad iothalamate clearance test, among others.
The treatment methods used in the market include the use of corticosteroid drugs, immunosuppressive drugs, ACE inhibitors and ARBs, among others.
The condition, on the basis of type, can be categorised into primary and secondary IgA nephropathy.
The major symptoms include haematuria, proteinuria, and oedema, among others.
Anyone can suffer from this condition, including adults and children.
The routes of administration include oral and parenteral, among other methods.
The leading distribution channels for drugs include hospital pharmacy, retail pharmacy, online pharmacy, and direct tender, among others.
The end-use sectors include hospitals, clinics, and home healthcare, among others.
The treatment channels in the market include public and private, among others.
The key players in the market include Novartis AG, Calliditas Therapeutics AB, Chinook Therapeutics Inc., Travere Therapeutics Inc., Omeros Corporation, VIFOR Pharma, Vera Therapeutics Inc., Merck KGaA, Reata Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., and Otsuka Pharmaceutical Co. Ltd, among others.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.